The landscape of therapeutics for Niemann-Pick Disease Type C (NPC) is a rapidly changing one, with significant strides being made in investigation. Several hopeful therapeutic methods are currently undergoing clinical trials, offering optimism for sufferers living with this rare and progressive brain-related disorder. A mixture of pharmacological